SloveniaSeven-year-old Miloš, who has been living with a severe form of bullous epidermolysis since birth, recently received his fourth dose of gene therapy at the University Clinical Center Ljubljana in Slovenia. Diagnosed with dystrophic epidermolysis bullosa, Miloš experiences extreme fragility of his skin, where even minor pressure or touch can cause blisters, open wounds, and bleeding. He was the first patient in Slovenia to receive the revolutionary gene therapy Vyjuvek, which had previously only been available in the United States. After months of advocacy by his family and the William July Society, the treatment was made accessible through the Slovenian Health Insurance Fund. Miloš remains cheerful and optimistic despite his condition, expressing happiness after each treatment. The new gene therapy directly targets the underlying genetic defect, delivering a functional copy of the gene responsible for producing a protein essential for skin integrity. This advancement offers hope for improved quality of life for patients dealing with chronic wounds and pain.
Bias read (Center): The article focuses on medical progress and healthcare accessibility rather than political ideology or partisan framing. While it mentions bureaucratic efforts and advocacy, these are presented as factual challenges rather than politically charged narratives. The tone remains neutral, emphasizing a
